GlassScriptPhysician profile
Taylor P Spera
NPI 1558734889
$6,748.95
in general payments reported to CMS, 2019-2025
27 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,002 · 2022: $1,336 · 2023: $1,363 · 2024: $1,705 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,132 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,132.03 |
| Education | $278.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,245.07 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,000.47 | 2021-2025 | |
| Lilly USA, LLC | $863.59 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $756.89 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Regeneron Healthcare Solutions, INC. | $393.41 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $389.45 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $370.43 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Leo Pharma INC. | $353.38 | 2021-2025 | Adbry |
| Amgen INC. | $178.61 | 2022-2025 | Otezla, Otezla |
| Genzyme Corporation | $168.02 | 2021-2024 | |
| Galderma Laboratories, L.P. | $151.58 | 2021-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $140.33 | 2022-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $97.66 | 2021-2024 | Cabtreo, Jublia |
| Pfizer INC. | $92.63 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $90.75 | 2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $74.34 | 2023-2024 | Zoryve |
| Biofrontera INC. | $40.77 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Merz North America, INC. | $39.98 | 2022-2023 | Xeomin |
| Journey Medical Corporation | $37.61 | 2022-2023 | |
| Organogenesis INC. | $32.83 | 2022 | |
| Kyowa Kirin, INC. | $32.50 | 2023-2024 | Poteligeo |
| Integra Lifesciences Corporation | $24.84 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.94 | 2022 | |
| Organon LLC | $19.75 | 2024 | |
| Incyte Corporation | $19.30 | 2025 | Opzelura |
| Mayne Pharma Commercial LLC | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Spera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.